Fundraising Fox
/Companies
Sign in

Abiologics

26 employees on LinkedIn · 1 known investors

Find your way into Abiologics

Each arrow is one introduction. Sign up to fill in the first one.

204 people can intro you to Avak

Ask Noubar Afeyan to introduce you to Avak Kahvejian

You →Noubar · together at Cygnal Therapeutics →Avak

190 people can intro you to Maria-Chiara

Ask Jamie Chen to introduce you to Maria-Chiara Magnone

You →Jamie · together at Abiologics →Maria-Chiara

124 people can intro you to Jaclyn

Ask Sam Okafor to introduce you to Jaclyn Dunphy

You →Sam · together at Flagship Pioneering →Jaclyn

Sign up to find every way you can get introduced to Abiologics

  • Your email: who you already know at Abiologics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Abiologics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

AKAvak Kahvejian
Avak KahvejianChairman (Founder / founding CEO)Avak Kahvejian was involved in conceiving and launching platform companies at Flagship Pioneering that leveraged new biological mechanisms and biotechnologies before founding Abiologics.
M
MikeChief Innovation Officer & Co-Founder
JDJaclyn Dunphy
Jaclyn DunphyCo-Founder & Senior Director of Strategy and Research OperationsCo-founder and Senior Director of Strategy and Research Operations at Abiologics, where she helped originate the company's scientific approach to designer D-protein therapeutics. Abiologics uses computational design to create protein-inspired molecules called Synteins intended to serve as a new class of therapeutics.
MMMaria-Chiara Magnone
Maria-Chiara MagnoneChief Scientific OfficerShe has held executive roles in pharmaceuticals and academia-pharma partnerships, with expertise in drug discovery, translational sciences, and clinical development, with prior focus on chronic kidney disease and precision medicine approaches in cardiovascular and metabolic disease.

Investors · 1

Frequently asked questions

What does Abiologics do?
Abiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
Who founded Abiologics?
Abiologics was founded by Avak Kahvejian, Mike, Jaclyn Dunphy.
Who are Abiologics's investors?
Abiologics's investors include Flagship Pioneering.